World TB Day 2023 – ‘Yes! We Can End TB!’

Tuberculosis (TB) is a disease caused by Mycobacterium tuberculosis that primarily affects the lungs. It is a global health problem, with nearly 10 million people falling ill with TB and 1.4 million dying yearly. The World Health Organization (Read More)declared TB one of the top 10 causes of death. Despite significant progress in diagnosing and treating TB, the disease remains a major public health threat, especially in low- and middle-income countries.

Trana Discovery is a biopharmaceutical company developing novel therapies for infectious diseases, including TB. Trana shares the belief of the National Institutes of Health (NIH) that we can end TB. On World TB Day, Trana echoed the sentiment of the NIH and reiterated its commitment to eradicating TB.

The fight against TB has been going on for 140 years. Many approaches have been used to try and eliminate the disease during this time. However, the traditional broad-spectrum approach to treating TB has its limitations. For example, antibiotics used in this approach are not selective and can harm both pathogenic and beneficial bacteria in the body. This approach can also lead to the development of drug-resistant strains of bacteria.

Trana has devised a different strategy to combat TB. Instead of using the traditional broad-spectrum approach, Trana’s plan involves identifying innovative agents that specifically target the cause of the disease, Mycobacterium tuberculosis. The goal is to develop a bio-selective antibiotic to selectively target the pathogen without harming the normal GI flora. This approach can potentially reduce antibiotic resistance and address other Mycobacterium species, such as M. avium, which can cause diseases such as lymphadenitis and disseminated infections in immunocompromised individuals.

Trana’s approach to developing a bio-selective antibiotic involves using cutting-edge technologies such as computational chemistry, artificial intelligence, and machine learning. These technologies enable Trana to design and test a large number of potential drugs in a short period. Trana’s approach also involves collaboration with academic institutions, research organizations, and government agencies to accelerate drug discovery and development.

In conclusion, Trana Discovery shares the NIH’s belief that we can end TB. Trana’s strategy to develop a bio-selective antibiotic that can selectively target Mycobacterium tuberculosis without harming the normal GI flora has the potential to revolutionize the treatment of TB. Trana Discovery’s innovative approach and its use of cutting-edge technologies make it a leader in drug discovery and development. With continued collaboration and investment, we can end TB and improve people’s health worldwide.